Helix Therapeutics’ proprietary targeted gene modification (TGM) technology is just one example of the many exciting technologies being spun out of Yale University. About a year ago the startup company licensed the technology from Yale on an exclusive worldwide basis. Developed in the lab of Dr. Peter Glazer, a founder of Helix and one of its board members, the technology is being utilized by Helix to develop therapies for HIV/AIDS and genetic disorders, such as sickle cell anemia, B-Thalassemia, Hurler’s Syndrome and Gaucher’s Disease.

CI recently strengthened its support of Helix by making a follow-on investment in the company. Click here to read our press release.

We are in the process of exploring other Yale-grown technologies with hopes that there will be additional partnership opportunities for CI – where our early-stage support can make a difference in helping launch startup companies.

Russell Tweeddale
Managing Director, Investments

View comments / leave a comment

Posted under From the Deal Team